Bill > H1359

This bill aims to ensure affordable access to epinephrine autoinjectors for treating anaphylaxis by modifying health insurance coverage regulations. Specifically, the bill requires that health insurance plans cover epinephrine autoinjectors as a treatment for anaphylaxis, an acute and potentially life-threatening allergic reaction. The legislation mandates that coverage for either one brand-name or one generic epinephrine autoinjector will have no deductible or co-insurance, and the co-payment will be capped at $60 for a two-pack of autoinjectors. The bill amends several sections of existing law to include anaphylaxis as an acute condition and specifically mentions epinephrine autoinjectors as a treatment for this condition. These changes will apply to all health insurance contracts entered into, renewed, or amended on or after July 1, 2026, which will help ensure that individuals with severe allergies can more easily access this critical emergency medication at a predictable and affordable price.

Budget and Finance, Business and Industry, Health and Social Services

https://malegislature.gov/Bills/194/H1359